We are pioneering a new therapeutic approach to treat debilitating ear, nose and throat (ENT) diseases that impact the lives of millions of people.
Our first product candidate targets chronic rhinosinusitis (CRS), which affects about 27 million - 11% of adults - in the U.S., and has no approved pharmaceutical treaments.
Nov 26, 2019 Lyra Therapeutics To Present at the Evercore ISI 2nd Annual HealthCONx Conference
Nov 19, 2019 Lyra Therapeutics Appoints Bradford Smith to its Board of Directors
